First Gene Therapy Targeting Brain White Matter Shows Breakthrough Results in Fatal Childhood Disease
核心洞察
Eight children with Canavan disease (搜索) showed increased myelin volume on brain scans and significant improvement in developmental milestones after receiving the first gene therapy specifically targeting oligodendrocytes (搜索).
The MYR-101 therapy directly addresses the core pathology by delivering a healthy copy of the ASPA (搜索) gene exclusively to oligodendrocytes (搜索), the brain cells responsible for producing protective myelin coating.
All participants tolerated the treatment well with no serious side effects, and the FDA has granted fast-track designation while the UK regulatory agency has admitted it to the innovative licensing pathway.
Children with a fatal brain disorder showed significant improvements after receiving gene therapy in an early-stage clinical trial, marking the first successful treatment to restore myelin in the brain's white matter. All eight participants with Canavan disease (搜索) enrolled in the trial demonstrated increased myelin volume on brain scans and significant improvement in developmental milestones compared with the typical course of the disease.
"In 25 years working with this patient population, I have never seen more impressive results," said Paola Leone, professor of cell biology at Rowan University in Glassboro, New Jersey, and lead author of the study published in Nature Medicine. "Their quality of life has completely changed."
Targeting the Root Cause
Canavan disease (搜索) is a rare genetic condition mainly affecting infants and young children, causing severe developmental delays, neurological difficulties, and reduced life expectancy. Most affected children do not survive past age 10. A mutation in the ASPA (搜索) gene disrupts the function of oligodendrocytes (搜索), the cells that make the protective myelin that insulates nerve fibres.
The trial used a new form of gene therapy called MYR-101, designed to deliver a healthy copy of the gene directly and exclusively into oligodendrocytes (搜索). Earlier attempts targeting other types of brain cells failed to show any improvement in the condition.
"For the first time, we're seeing clear biological and functional evidence that gene therapy targeting oligodendrocytes (搜索) can directly address the core pathology of this disease," said Dr Michael Muhonen, co-chief medical officer of Myrtelle (搜索), the company behind the clinical trial.
Unprecedented Clinical Outcomes
Leone's team reported improved brain development, reduced toxic buildup, and in some cases, children achieving milestones once thought impossible. "We've seen brain structures grow, brain function improve; we're seeing patients walk with minimal assistance," Leone explained.
The treatment was well tolerated by all participants, with no serious side effects linked to the therapy. There are no disease-modifying treatments available for Canavan disease (搜索), and current therapies are supportive only.
Regulatory Recognition and Future Prospects
The US Food and Drug Administration has already given the drug fast-track designation, and the UK's Medicines and Healthcare products Regulatory Agency has granted admission to the innovative licensing and access pathway. Leone believes regulatory approval could come as early as next year.
The breakthrough came after decades of research and a crucial turning point in 2017 when Leone met a Brooklyn family with two children newly diagnosed with Canavan disease (搜索). Within weeks, the family's grassroots campaign raised $1.5 million to launch Leone's next round of research through the establishment of the Cure Canavan Fund (搜索).
Broader Implications for Neurological Disorders
The implications reach far beyond Canavan disease (搜索), as Leone's team is already applying similar strategies to other neurological disorders, including multiple sclerosis (搜索), multiple system atrophy (搜索), frontotemporal dementia (搜索) and motor neuron disorders (搜索).
"This is not the end but the beginning of a new era in the treatment of neurological disorders, conditions that, at their core, involve impaired white matter," Leone said. Myrtelle (搜索) plans to keep monitoring the patients to assess the long-term efficacy while working to make this therapy more widely available.